Variant Bio
variantbio.com
Actively hiring
Medical AI
Drug Discovery
Genomics & Genetic Testing
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$127.7M
3 rounds on record
Latest round
$105M
Venture round · Oct 2021 · 4 yr ago
Team
37
US Form 5500 (plan participants) · Dec 2024
Backers
1
Alta Partners
The money's age
Long since its last round
59 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 6
Launched Variant Bio Launches Inference, the World · PRNewswire
Jan 7, 2025
Won a customer Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M · GeekWire
Oct 29, 2021
Raised a round Venture round $105M · SEC Form D
Jul 28, 2020
Raised a round Venture round $6.1M · SEC Form D
Sep 27, 2019
Raised a round Venture round $16.6M · SEC Form D
2018
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2021 | $105M | — | SEC Form D |
| Venture round | Jul 2020 | $6.1M | — | SEC Form D |
| Venture round | Sep 2019 | $16.6M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Variant Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kaja WasikExecutive Officer, DirectorSEC Form D
Akhila KosarajuExecutive Officer, DirectorSEC Form D
Josh WolfeDirectorSEC Form D
Andrew FarnumExecutive Officer, DirectorSEC Form D
Stephane CastelExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Alta Partners Similar startupsby what they do, their industry and backers
Draupnir Bio is developing new innovative therapies for patients.
Talus Bio makes the regulome—the control layer of gene expression—visible, measuring and modulating gene regulators in live cells to access…
SWAN Genomics is developing a plasmonic nanoantenna-based single-molecule DNA sequencing platform. Sequencing With A Nanoantenna.
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs".
Our vision is to accelerate the time to impact of new life-saving therapies in lung and heart disease.
Humane Genomics develops cancer therapies by engineering cancer-killing RNA viruses using a synthetic biology platform.
News
Variant Bio Expands Target Discovery Collaboration with Boehringer Ingelheim into Cardiovascular Disease
Variant Bio, a genomics-driven AI drug discovery company, today announced an expansion of its multi-year research collaboration and license agreement with Boehringer Ingelheim. Building on the companies
Read more
Report
Variant Bio Expands Target Discovery Collaboration with Boehringer Ingelheim into Cardiovascular Disease
/PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery company, today announced an expansion of its multi-year research collaboration and license...
Read more
Report
The Global Diversity of Human Genetics
Boehringer adds 250M to value of Variant pact by expanding into cardiovascular disease Fierce Biotech - September 23, 2026
Read more
Report
Boehringer adds 250M to value of Variant pact by expanding into cardiovascular disease
Boehringer adds 250M to value of Variant pact by expanding into cardiovascular disease Fierce Biotech - September 23, 2026
Read more
Report
A genetic time capsule
Boehringer adds 250M to value of Variant pact by expanding into cardiovascular disease Fierce Biotech - September 23, 2026
Read more
Report
Boehringer continues kidney disease dealmaking run with 120M Variant Bio pact
Variant Bio Appoints Craig T. Basson, MD, PhD, to Advance Genomics-Driven Clinical Programs Press Release - January 21, 2026
Read more
Report
Variant Bio Attracts Boehringer With AI Discovery of Kidney Disease Targets - TimmermanReport.com
Please subscribe and tell your friends why it's worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your accoun
Read more
Report
Variant Bio Launches Inference, the World
/PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery company, today announced the launch of Inference, the world
Read more
Report
Variant Bio Announces Strategic Target Discovery Collaboration with Boehringer Ingelheim for Kidney Disease
/PRNewswire/ -- Variant Bio, a genomics-driven AI drug discovery company, today announced a multi-year research collaboration and license agreement with...
Read more
Report
Drug Company to Share Revenues With Indigenous People Who Donated Their Genes
Variant Bio Attracts Boehringer with AI Discovery of Kidney Disease Targets Timmerman Report - January 6, 2026 Boehringer continues kidney disease dealmaking run with 120M Variant Bio pact Fierce Biotech - January 6, 2026
Read more
Report
Show more news
People
Kaja Wasik
Executive Officer, Director
Akhila Kosaraju
Executive Officer, Director
Josh Wolfe
Director
Andrew Farnum
Executive Officer, Director
Stephane Castel
Executive Officer, Director
Adam Goulburn
Director
Julie Sunderland
Director
Bob More
Director
Stuart Nagae
Director
Elena Viboch
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
New York
United States
HQ
Seattle
United States
Regional office
Variant Bio